文献速递糖尿病肥胖与代谢综合征

2型糖尿病患者的用药增加与多重用药:2000至2020年丹麦经验

Increasing Medication Use and Polypharmacy in Type 2 Diabetes: The Danish Experience From 2000 to 2020.
PubMed 文献 · Diabetes Care · 2024-01-01

该研究利用丹麦全国登记数据,建立2000至2020年所有≥18岁2型糖尿病患者的队列,分析用药及多重用药(≥5或≥10种药物)的患病率,并按年龄、性别、慢性病数量和社会经济地位分层。结果显示,患者数从2000年的84,917例增至2020年的307,011例,人均每日用药从3.7±2.8种增至5.3±3.2种,终生暴露于≥5种和≥10种药物的风险分别为89%和47%。结论认为用药和多重用药增加,但对其适宜性不确定,强调医护人员需了解多重用药的潜在风险。

要点

  • 2000至2020年,丹麦2型糖尿病患者人均每日用药从3.7±2.8种增至5.3±3.2种。
  • 终生暴露于≥5种药物的风险为89%,暴露于≥10种药物的风险为47%。
  • 高龄、男性、较低社会经济地位和丹麦族裔与多重用药正相关,但不能解释整体增加。

核心结论

  • 2型糖尿病患者的用药和多重用药已增加,其含义和适宜性尚不确定,结果强调医护人员需了解多重用药的潜在风险,包括药物相互作用、不良反应以及处方不足和过度。

研究设计与样本

  • 基于丹麦国家登记数据建立2000至2020年所有≥18岁丹麦2型糖尿病患者的队列,分析用药及多重用药(≥5或≥10种药物)患病率,并按年龄、性别、慢性病数量和社会经济地位分层。

主要发现

  • 队列从2000年的84,917例患者增长至2020年的307,011例,总计461,849例独特患者。
  • 人均每日用药从2000年的3.7±2.8种增至2020年的5.3±3.2种。
  • 终生暴露于≥5种药物的风险为89%(409,062/461,849),暴露于≥10种药物的风险为47%(217,467/461,849)。
  • 增加由药物种类扩大驱动,其中镇痛药、降压药、质子泵抑制剂和他汀类的净增加最大。
  • 高龄、男性、较低社会经济地位和丹麦族裔与多重用药正相关,但不能解释多重用药的整体增加。

临床怎么用

  • 原文未据此给出推荐。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

OBJECTIVE: Type 2 diabetes often coexists with other conditions that are amenable to pharmacological treatment. We hypothesized that polypharmacy among individuals with type 2 diabetes has increased since 2000. RESEARCH DESIGN AND METHODS: Using Danish national registries, we established a cohort of all Danish individuals (aged ≥18 years) with type 2 diabetes between 2000 and 2020. We analyzed their medication use and prevalence of varying degrees of polypharmacy (≥5 or ≥10 medications), stratifying by age, sex, number of chronic diseases, and socioeconomic status. RESULTS: The cohort grew from 84,917 patients in 2000 to 307,011 in 2020, totaling 461,849 unique patients. The number of daily medications used per patient increased from (mean ± SD) 3.7 ± 2.8 (in 2000) to 5.3 ± 3.2 (in 2020). The lifetime risk of polypharmacy was substantial, with 89% (n = 409,062 of 461,849) being exposed to ≥5 medications at some point and 47% (n = 217,467 of 461,849) to ≥10 medications. The increases were driven by an expanding group of medications, with analgesics, antihypertensives, proton pump inhibitors, and statins having the largest net increase. Advanced age, male sex, lower socioeconomic status, and Danish ethnicity positively correlated with polypharmacy but could not explain the overall increase in polypharmacy. CONCLUSIONS: Medication use and polypharmacy have increased among patients with type 2 diabetes. Although the implications and appropriateness of this increased medication use are uncertain, the results stress the increasing need for health care personnel to understand the potential risks associated with polypharmacy, including medication interactions, adverse effects, and over- and underprescribing.

来源:Diabetes Care,查看原文。版权归原作者所有。

引用

  1. Johansson KS, Jimenez-Solem E, Petersen TS, et al. Increasing Medication Use and Polypharmacy in Type 2 Diabetes: The Danish Experience From 2000 to 2020. Diabetes Care. 2024. PMID: 38709662. doi:10.2337/dc24-0011

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。